NewCardio, Inc. (OTCBB: NWCI), a cardiac diagnostic and services company, today elected James A. Heisch to its Board of Directors, representing a new addition to the NewCardio Board and bringing the total number of Board members to five. Mr. Heisch is one of four independent directors.

Mr. Heisch brings more than 40 years of senior level business experience to NewCardio, including 17 years with Arthur Young & Company where he was an audit partner, and later as the Chief Financial Officer for leading technology companies including Atari, Businessland and Supermac Technology. Additionally, Mr. Heisch served five years with medical device company Vidamed, Inc., initially as CFO managing all financial and administrative functions in the United States and United Kingdom, and then as President and CEO responsible for worldwide operations. He later joined Worldtalk Corporation as CFO and later was promoted to President, which, under his leadership, was successfully sold to Tumbleweed Communications. Mr. Heisch served as interim President and CFO of Tumbleweed until June 2001, and continues to sit on Tumbleweed’s board of directors and serves as its Audit Committee Chairman.

Mr. Heisch has a bachelor’s degree in accounting from San Jose State University and an MBA from the Leavy School of Business at the University of Santa Clara. He earned his Certified Public Accountant (CPA) certification while working at Arthur Young.

Branislav Vajdic, Ph.D., President and Chief Executive Officer of NewCardio, Inc., commented, “Mr. Heisch brings a wealth of business experience to NewCardio, particularly expertise in managing rapid growth and accessing growth capital. With more than 40 years of senior leadership experience, and a proven track record of success, he makes an ideal addition to the NewCardio organization. I look forward to benefiting from his counsel and expertise as we execute on our business strategy.”

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide dramatically higher accuracy to, and thus significantly increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio’s development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. The company’s three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio intends to initially compete in two large segments of the CVD diagnostic market: cardiac safety in drug development and diagnostics. For more information, visit www.newcardio.com [1].